Member Info for daveycaferacer

it's a real bugbear of mine, BGNE's valuation, which has just hit $27bn. Their pipeline is not much bigger than Chi-Med's and their revenues are broadly similar, so based on current ttm numbers they are valued at about five times Chi-Med, which doesn't make sense to me

I continue to Buy Chi-Med!

The UK Govt cannot bail out every single sector, unless we become a Communist state

thankyou for highlighting the scmp article jatw

https://www.scmp.com/business/companies/article/3103842/billionaire-li-ka-shings-biotech-unit-hopes-new-cancer-drug

As of today, Chi-Med is responsible for the development and execution of all local and regional on-the-ground commercial activities in China for Elunate®. It’s a milestone that marks an important step forward for us as a commercial oncology company

https://twitter.com/HChiMed/status/1311458145093390336?s=20

Chi-Med Appoints Tom Held as Senior Vice President Commercial U.S.

We would like to extend a warm welcome to Tom Held, who today joins Hutchison MediPharma
International (HMPI), Chi-Med’s U.S. subsidiary, as Senior Vice President Commercial US. This hire is
the latest development in our strategy to expand our international footprint and supports our work to
build our R&D capabilities and bring our innovative medicines to cancer patients around the world.
Tom has over 30 years of experience in the pharmaceutical industry. Large swathes of his career have
been dedicated to commercial oncology, highlighted by his two decades at Novartis in various
positions. He brings this experience to a new role designed to grow our commercial presence and
infrastructure in the US. Tom will focus on the potential launch of surufatinib in its first market outside of
China, as well as on future launches through Chi-Med/HMPI’s commercial platform.
Marek Kania, Managing Director and Chief Medical Officer – International, commented, “We are
pleased that Tom is joining us on our journey as we look to bring our cutting-edge innovations to cancer
patients and advance our portfolio on a global scale. Tom brings deep experience in brand strategy,
broad commercial experience, and expertise in building fit-for-purpose teams to our efforts to expand
the HMPI customer facing footprint outside of China.”

Chi-Med Commences Expanded Commercial Activity with Elunate® in China

As of today, Chi-Med has commenced its expanded commercial activity with Elunate® in China.
Our commercial team will now be responsible for the development and execution of all local and
regional on-the-ground medical detailing, promotion and marketing activities, as announced on July 28,
2020. See here: https://www.chi-med.com/chi-med-and-lilly-to-collaborate-in-commercializing-elunatein-
china/
Hong Chen, Chief Commercial Officer – China, said, “Today’s milestone marks an important step
forward for Chi-Med as a commercial-stage biopharmaceutical company. We are proud to have built a
340-strong commercial team across the country to support these efforts and look forward to applying
our deep commercial knowhow developed through our established Commercial Platform.
Alongside this activity, we will continue with our highly successful collaboration with Lilly on the national
marketing strategy in China. The new structure of the agreement optimizes the resources of both
businesses and will undoubtedly maximize the potential of Elunate® in China, getting it to those in need
as effectively as possible.”

If approval comes by the end of this year there could be enough time to get it onto the NRDL midway through 2021, especially given that there is no effective alternative treatments.

It took 14.5 months from NDA acceptance to approval for Frquintinib in China

Surufatinib (non-pancreatic NET) NDA was submitted almost 12 months ago, which suggests we are probably very close to approval assuming there are no major issues .....

My opinion is that a NASDAQ and an HK listing are probably the most important. London is largely irrelevant for an Asian Biopharma but the Company may have reasons to maintain a UK listing. Whatever happens I am sure they will continue to have the interests of Shareholders and patients at the core of what they do.

they won't go under, they have over $50m in their Bank Account!

Gabriele mentions in a recent video that EFG Diagnostics spun out RENX which is a prognostic asset for liver cancer. It has since risen 273% which bodes well for Accustem as a similar asset in terms of addressable market, and a similar spin-out.

They would, but the other critical point is we have the only fully human IL6 antibody

"looking forward to the interview. "

it was yesterday

In the 5 trading days immediately following the last Bloomberg Red Chip Broadcast the share price increased by 67% ;o-)

According to today's Sunday Times we are now ranked at 105 in the UK's top Companies, and I am sure we will enter the top 100 soon. A Main Market listing would be a huge boost as Tracker Funds would be compelled to buy, but that will not happen whilst on AIM. I wonder if being in the top 100 Companies would give increased weight to reconsidering a Main Listing?

looking forward to the Red Chip broadcast on Bloomberg but Dave really does need to stop wearing cheap pre-tied bow-ties, which is the ultimate faux pas, tie-able bow ties are essential - he needs to look at Tom Keene for reference!

another interview conducted by Dave, a Tom Keene wannabee

The last one provided a short lived boost to the share price, as Red Chip Money has a large audience of Individual Investors in the United States

Share buyback would send a very negative signal to the market, they raised capital to accelerate the clinical programs not prop up the share price for short term daytraders and investors

If you set a sell limit order with a date in the future then shares cannot be lent out, so that is the best thing to do. You can set a reasonably high price to prevent them being sold. Most Brokers will only allow a Limit order to run for 30 days, at which point it automatically expires.

Thankyou amones, I had forgotten about the Shanghai -London Stock Connect, maybe Chi-Med would consider moving to a Main Listing in order to take advantage of this system, allowing Chinese Investors access, although if the HK listing is back on maybe that would not be a priority.

I've been closely watching Beigene since their IPO in Feb 2016, they have since risen 8 fold and have EV/Sales metrics of 74, an mcap of $25 billion and yet have similar revenues to us (but bigger losses and a bigger cash balance). We are under-valued on that basis and also on future DCF numbers. I'm still hopeful for a decent re-rating as the pipeline ramps up . The big prize will be Savo outside of China, but there's still plenty more in the meantime to drive the valuation forward.